Indivior Completes U.S. Domestication and Governance Realignment

Indivior ( (INDV) ) has issued an announcement.

On January 26, 2026, Indivior U.S. announced the effectiveness of a court-approved Scheme of Arrangement and the completion of its U.S. Domestication, under which Indivior Pharmaceuticals, Inc. became the ultimate parent of Indivior U.K., each Indivior U.K. ordinary share was exchanged for Indivior U.S. common stock, and the company’s financial reporting and capital structure shifted from the U.K. to a Delaware, U.S.-listed framework. In connection with the change of domicile, the company amended its existing Note Purchase Agreement so that financial statements and related covenants are now reported at the U.S. top company level, put in place broad indemnification agreements for directors and executive officers, replicated the prior U.K. board and committee structure under Indivior U.S., assumed and updated legacy equity incentive and savings plans while adopting a new 2026 Omnibus Equity Incentive Plan and a detailed non-employee director compensation policy, and implemented a Delaware-style charter and bylaws featuring anti-takeover protections, director election mechanics, and forum-selection and indemnification provisions that collectively strengthen its U.S. corporate governance framework and may influence control contests and stockholder litigation dynamics.

The most recent analyst rating on (INDV) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.

Spark’s Take on INDV Stock

According to Spark, TipRanks’ AI Analyst, INDV is a Outperform.

Score is driven by the operational rebound and constructive momentum (strong profitability recovery and positive trend/indicators), supported by upbeat guidance and cost-savings plans. It is held back by balance-sheet risk from negative equity and a relatively high P/E that leaves less room for execution missteps.

To see Spark’s full report on INDV stock, click here.

More about Indivior

Indivior, now domiciled in the United States as Indivior U.S., is a specialty pharmaceutical company whose shares trade on the Nasdaq Global Select Market under the ticker “INDV.” The company has authorized 700 million shares of common stock and 70 million shares of preferred stock, and its capital structure and governance are organized under Delaware law, with a single class of common stock carrying one vote per share and various anti-takeover and governance provisions intended to shape stockholder rights and board control.

Average Trading Volume: 2,600,812

Technical Sentiment Signal: Buy

Current Market Cap: $4.12B

For a thorough assessment of INDV stock, go to TipRanks’ Stock Analysis page.